Return to site

PhaBuilder Secures 359 Million Yuan in Funding to Advance Green and Low-Carbon Living

Pioneering Robotics and AI Solutions Provider to Enhance R&D Capabilities and Foster Global Biopharmaceutical Advancements

February 3, 2023

Beijing PhaBuilder Biotechnology Co., Ltd. announced the completion of a 359 million yuan Series A+ financing round. This funding will further enhance the R&D capabilities of the Synthetic Biology Innovation Center, advance the construction of a large-scale PHA (Polyhydroxyalkanoates) production line, and accelerate the development and global business expansion of "PHA Life" green and low-carbon lifestyle products.

 

PHA (Polyhydroxyalkanoates) is a biodegradable polymer synthesized by microorganisms. PhaBuilder has developed multiple types of PHA product pipelines, including PHB, PHBV, and different ratios of P34HB, which are widely applied in fields such as medical, fashion, 3D printing, and everyday packaging.

 

With the core concept of "PHA Life," PhaBuilder is committed to promoting a green and low-carbon lifestyle. By integrating industry upstream and downstream resources and partnering with collaborators, PhaBuilder aims to create a green and low-carbon lifestyle centered around PHA. This includes promoting the use of biodegradable PHA products as alternatives to traditional plastics, changing consumer habits and lifestyles, and advocating for sustainable development and environmental protection.

 

PhaBuilder will collaborate closely with its partners to collectively promote the realization of a green and low-carbon lifestyle centered around PHA. It strives to provide more environmentally friendly and sustainable choices to society and contribute to the construction of a sustainable future.

 

 

Disclaimer: Despite our efforts to maintain accuracy, errors are unavoidable due to our limited expertise. Some information may not be up to date, and we welcome your feedback to make necessary corrections. This document is intended solely for the purpose of providing a business-oriented and written introduction to the field of synthetic biology. It does not constitute any investment advice. We appreciate your understanding.